Translational research bridges the bench and the patient: validating on large populations what has been discovered in the laboratory, and turning a molecular observation into information useful for clinical decision-making. Inovarion intervenes at this stage through the analysis of data from large patient cohorts, often multicentre and international. The validation of the Immunoscore is its most striking illustration: Inovarion’s scientists contributed to it on large numbers, across several continents.
This approach draws on clinical samples and biopsies, on genome-wide association studies (GWAS) and polygenic risk scores, and on a solid toolkit of biostatistics and epidemiology — overall and relapse-free survival analyses, Cox regression, Kaplan-Meier curves, Mendelian randomisation, retrospective and prospective studies.
The applications cover two major strands. In oncology, the clinical validation of prognostic and predictive biomarkers — the Immunoscore in colon cancer, through the international multicentre SITC study conducted across several continents[8] — links the tumour’s immune profile to survival and to the response to chemotherapy. In infectious diseases, the genetics and epidemiology of cystic fibrosis patient populations have shed light on susceptibility to respiratory infections[3], the role of modifier genes[11] and the seasonal influence of infectious episodes[4]. This work has appeared in leading journals, including the Journal of Clinical Oncology and the European Respiratory Journal.
This strand naturally extends bioinformatics (statistical analyses, GWAS) and imaging (the digital pathology of the Immunoscore, whose clinical value rests precisely on these cohorts): it is the step where molecular data meets the patient’s outcome. True to its positioning — from fundamental discoveries through to clinical applications — Inovarion brings its command of cohort analysis, biomarker validation and biostatistics to its partners’ translational projects.
See also: Immunoscore.
Contact an expert · See all publications
Representative publications
- Benattia et al. Blood MMP-7 and TNF-α levels as potential prognostic biomarkers for adult pulmonary Langerhans cell histiocytosis. Scientific Reports, 2026. PubMed
- Tragin et al. Muscle Spatial Transcriptomic Reveals Heterogeneous Profiles in Juvenile Dermatomyositis and Persistence of Abnormal Signature After Remission. Cells, 2025. Record → · PubMed
- Lin et al. Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J, 2024. Record → · PubMed
- Mésinèle et al. Seasonal and climatic influence on respiratory infections in children with cystic fibrosis. Scientific Reports, 2024. Record → · PubMed
- Mlecnik et al. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. Cancers (Basel), 2023. Record → · PubMed
- Mésinèle et al. Airway infections as a risk factor for Pseudomonas aeruginosa acquisition and chronic colonisation in children with cystic fibrosis. J Cyst Fibros, 2023. Record → · PubMed
- Mlecnik et al. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers (Basel), 2022. Record → · PubMed
- Mlecnik et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020. Record → · PubMed
- Lupinacci et al. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Gastroenterology, 2018. Record → · PubMed
- Eynde et al. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Cancer Cell, 2018. Record → · PubMed
- Mésinèle et al. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes. Int J Mol Sci, 2022. Record → · PubMed